08 Dec 2025
7m
ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.